New immune cell therapy takes on tough pancreatic cancer
NCT ID NCT07553793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new type of cell therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy. The treatment uses a patient's own immune cells, called macrophages, that are engineered in a lab to recognize and attack cancer cells carrying a protein called C-MET. The study will enroll 18 participants to check the safety of the treatment and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-M-C-MET cells (engineered immune cells)
- What this could lead to
- If this works, it could offer a new treatment option for advanced pancreatic cancer patients who have run out of standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, so it is not yet clear if the treatment is safe or effective. There is a risk of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED STAGE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?